Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Jialiang Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1626-6674; OpenAlex author ID A5100638391. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 4 papers · 2022: none · 2023: 4 papers · 2024: 1 paper · 2025: 6 papers · 2026: 1 paper

Papers 17

  1. NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis. Co-author DOI 10.1136/gutjnl-2025-336541↗
  2. Identification of novel plasma proteins as promising noninvasive biomarker for early diagnosis and surveillance of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-025-02252-w↗
  3. Correction: Identification of novel plasma proteins as promising noninvasive biomarker for early diagnosis and surveillance of pancreatic ductal adenocarcinoma Co-author DOI 10.1007/s00535-025-02274-4↗
  4. Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy. Co-author DOI 10.1016/j.cmet.2025.10.015↗
  5. CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer. Last author DOI 10.1038/s41418-025-01464-0↗
  6. Psychological stress-induced ALKBH5 deficiency promotes tumour innervation and pancreatic cancer via extracellular vesicle transfer of RNA. Co-author DOI 10.1038/s41556-025-01667-0↗
  7. Targeting MXD1 sensitises pancreatic cancer to trametinib. Co-author DOI 10.1136/gutjnl-2024-333408↗
  8. KHSRP Stabilizes m6A-Modified Transcripts to Activate FAK Signaling and Promote Pancreatic Ductal Adenocarcinoma Progression. Last author DOI 10.1158/0008-5472.can-24-0927↗
  9. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Co-author DOI 10.1038/s41418-023-01225-x↗
  10. CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. Co-author DOI 10.1038/s41467-023-41861-y↗
  11. Super-enhancer RNA m6A promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-023-01568-8↗
  12. N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-22-3346↗
  13. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  14. N6 -methyladenosine-Mediated Upregulation of WTAPP1 Promotes WTAP Translation and Wnt Signaling to Facilitate Pancreatic Cancer Progression. First author DOI 10.1158/0008-5472.can-21-0494↗
  15. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1172/jci148130↗
  16. Genome-wide identification and characterization of circular RNA m6A modification in pancreatic cancer. Co-author DOI 10.1186/s13073-021-01002-w↗
  17. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lingxing Zeng · 15 shared papers, 2021–2026 · strength 2.39
  2. Xudong Huang · 14 shared papers, 2021–2026 · strength 2.10
  3. Jian Zheng · 14 shared papers, 2019–2025 · strength 1.94
  4. Dongxin Lin · 14 shared papers, 2019–2025 · strength 1.94
  5. Ziming Chen · 9 shared papers, 2023–2026 · strength 1.67
  6. Zilan Xu · 9 shared papers, 2023–2026 · strength 1.67
  7. Chunling Xue · 9 shared papers, 2023–2026 · strength 1.67
  8. Jiachun Su · 12 shared papers, 2019–2026 · strength 1.65
  9. Shaoping Zhang · 11 shared papers, 2021–2025 · strength 1.58
  10. Rufu Chen · 9 shared papers, 2019–2024 · strength 1.05
  11. Quanbo Zhou · 6 shared papers, 2023–2025 · strength 0.91
  12. Xiaowei He · 5 shared papers, 2023–2025 · strength 0.86
  13. Yanfen Zheng · 7 shared papers, 2019–2023 · strength 0.75
  14. Rui Li · 5 shared papers, 2021–2024 · strength 0.68
  15. Ying Ye · 6 shared papers, 2019–2023 · strength 0.64
  16. Zhixiang Zuo · 5 shared papers, 2019–2023 · strength 0.55
  17. Junge Deng · 5 shared papers, 2021–2023 · strength 0.54
  18. Guandi Wu · 4 shared papers, 2021–2023 · strength 0.44
  19. Lusheng Wei · 4 shared papers, 2021 · strength 0.40
  20. Shuang Liu · 2 shared papers, 2025 · strength 0.39
  21. Lu Zheng · 2 shared papers, 2025 · strength 0.39
  22. Xiaoyu Wu · 2 shared papers, 2025 · strength 0.38
  23. Ling Pan · 4 shared papers, 2019–2021 · strength 0.36
  24. Xu Che · 3 shared papers, 2019–2021 · strength 0.26
  25. Chen Hsuan Wu · 3 shared papers, 2019–2021 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.